Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Daiichi Sankyo
Deloitte
Moodys
Dow
Johnson and Johnson
US Army
Boehringer Ingelheim
Covington

Generated: November 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020080

« Back to Dashboard

NDA 020080 describes IMITREX STATDOSE, which is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from two suppliers. Additional details are available on the IMITREX STATDOSE profile page.

The generic ingredient in IMITREX STATDOSE is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 020080
Tradename:IMITREX STATDOSE
Applicant:Glaxosmithkline
Ingredient:sumatriptan succinate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020080
Suppliers and Packaging for NDA: 020080
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IMITREX sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080 NDA GlaxoSmithKline LLC 0173-0449 0173-0449-02 5 VIAL in 1 CARTON (0173-0449-02) > .5 mL in 1 VIAL
IMITREX sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080 NDA GlaxoSmithKline LLC 0173-0478 0173-0478-00 2 SYRINGE in 1 CARTON (0173-0478-00) > .5 mL in 1 SYRINGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrengthEQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Approval Date:Dec 28, 1992TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrengthEQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)
Approval Date:Feb 1, 2006TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrengthEQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Approval Date:Dec 23, 1996TE:ABRLD:Yes

Expired US Patents for NDA 020080

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline IMITREX sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-001 Dec 28, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-002 Feb 1, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline IMITREX sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-001 Dec 28, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
AstraZeneca
Moodys
Federal Trade Commission
Express Scripts
McKesson
Boehringer Ingelheim
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.